ArticleCureus2025
A Severe Case of Nuclear Matrix Protein-2-Positive Dermatomyositis With Negative Malignancy Workup.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Bladder carcinoma associated with anti-NXP2-positive inflammatory myopathy: a case-based review.Rheumatology international · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is an immune-mediated inflammatory myopathy that can present with proximal muscle weakness and characteristic skin findings. Nuclear matrix protein 2 (NXP-2)-positive DM, while rare, has a strong association with malignancy. It can display features such as muscle weakness, subcutaneous edema, and refractory dysphagia, all of which were present in our 63-year-old male patient. He experienced a prolonged hospitalization and percutaneous endoscopic gastrostomy (PEG) tube placement. He improved with prednisone, azathioprine, rituximab, and intravenous immunoglobulin (IVIG) treatments. For over two years, he has had no evidence of malignancy. This case underscores the complexity of NXP-2-positive DM and the potential for severe presentations that may require the usage of second-line therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.